Osimertinib (Tagrisso) has been TGA registered as adjuvant therapy after tumour resection in early stage, EGFR-mutated non-small cell lung cancer (NSCLC). The EGFR tyrosine kinase inhibitor is the first targeted therapy available to prevent recurrence of disease in this patient group. The evidence comes from the international ADAURA trial, which included Australian sites and investigators. ...
Osimertinib approved for early stage NSCLC
By Mardi Chapman
31 May 2021